Repligen (RGEN) Net Equity Issued and Repurchased (2019 - 2023)
Repligen's (RGEN) quarterly Net Equity Issued and Repurchased came in at -$10000.0 in Q3 2023, down 100.01% quarter-over-quarter from $131.1 million in Q3 2019.
Powered by 
Analysis
Repligen (RGEN) Net Equity Issued and Repurchased (2019 - 2023) Analysis & Trends
Repligen (RGEN) has reported Net Equity Issued and Repurchased for 2 consecutive years, with -$10000.0 the latest figure, recorded in Q3 2023.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$10000.0 in Q3 2023; TTM through Sep 2023 was -$10000.0, a 100.01% decrease from a year earlier, with the FY2020 full-year figure at $297.8 million, down 7.15% from the prior year.
- Net Equity Issued and Repurchased was -$10000.0 for Q3 2023 at Repligen, down from $131.1 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $131.1 million in Q3 2019 and troughed at -$10000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | - |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | - |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | - |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | - |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | - |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | - |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | 4.20 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | - |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | - |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | - |